X4 Pharmaceuticals and Norgine: A Strategic Partnership for Global Expansion

X4 Pharmaceuticals (Nasdaq: XFOR) and Norgine, a leading European specialist pharmaceutical company, have entered into an exclusive licensing and supply agreement to commercialize mavorixafor in Europe, Australia, and New Zealand. This strategic partnership aims to maximize the global potential of mavorixafor, a selective CXCR4 receptor antagonist, and bring transformative therapies to patients in need in these key strategic territories.

Under the terms of the agreement, X4 will receive €28.5 million in upfront consideration, along with up to €226 million in potential regulatory and commercial milestone payments, in addition to escalating double-digit royalties of up to the mid-twenties on any future net sales in the licensed territories. X4 and Norgine will collaborate closely on regulatory filings, with X4 continuing to be responsible for the ongoing global, pivotal Phase 3 4WARD clinical trial evaluating mavorixafor in chronic neutropenia. Norgine will be responsible for all market access and commercialization activities and will eventually hold all marketing authorizations in the licensed territories. X4 will manufacture and supply mavorixafor to Norgine.

This partnership is a significant milestone for X4, as it seeks to expand the reach of mavorixafor and bring in funding for its ongoing global, Phase 3 trial in chronic neutropenia. Norgine's impressive infrastructure and successful commercialization track record in specialty pharmaceuticals make it an ideal partner for X4. Additionally, both companies share a focus on putting patients first, ensuring that this collaboration will work towards improving the lives of people with rare immune disorders.

Janneke van der Kamp, Chief Executive Officer of Norgine, commented on the announcement: "We are very pleased to partner with X4 in this underserved, rare disease space and expand access to mavorixafor to patients in Europe, Australia, and New Zealand. If approved by the respective regulatory bodies, mavorixafor would be the first treatment targeting a key underlying cause of WHIM syndrome, a disease characterized by low white blood cell counts and frequent and/or serious infections. Through this agreement, we continue to expand our innovative portfolio of products and our expertise across rare diseases and specialty markets. This important milestone for our company further underscores Norgine’s position as a partner of choice across Europe and ANZ."

Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals, stated: "This strategic agreement is a significant milestone for X4 as we seek to maximize the global potential of mavorixafor and bring in funding for our ongoing global, Phase 3 trial in chronic neutropenia. We believe Norgine to be the ideal partner due to their impressive infrastructure and successful commercialization track record in specialty pharmaceuticals, as well as a shared focus on putting patients first. We look forward to expanding access to mavorixafor and continuing to address the unmet needs of those with rare immune disorders."